Literature DB >> 8308123

Methodological approaches to disinfection of human hepatitis B virus.

D L Prince1, H N Prince, O Thraenhart, E Muchmore, E Bonder, J Pugh.   

Abstract

Three commercial disinfectants (two quaternary formulations and one phenolic) were tested against human hepatitis B virus (HHBV). The treated virus was assayed for infectivity by the chimpanzee assay and for morphological alteration by the Morphological Alteration and Disintegration Test. The same agents were tested against duck hepatitis B virus in a duck hepatocyte infectivity assay. It is apparent that human and duck hepatitis viruses were relatively susceptible to disinfection, becoming noninfectious after < or = 10 min of contact with the disinfectant. The Morphological Alteration and Disintegration Test accurately predicted activity in the two infectivity tests. The anti-human hepatitis B virus effect of the low-level quaternary ammonium germicides is a novel finding and suggest that members of the family Hepadnaviridae are relatively susceptible to chemical agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8308123      PMCID: PMC266406          DOI: 10.1128/jcm.31.12.3296-3304.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Chimpanzees in captivity: humane handling and breeding within the confines imposed by medical research and testing. Position paper for the Jane Goodall Institute Workshop on Psychological Well-Being of Captive Chimpanzees 1st to 3rd December, 1987.

Authors:  J Moor-Jankowski; C J Mahoney
Journal:  J Med Primatol       Date:  1989       Impact factor: 0.667

2.  Hepatitis virus: effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains.

Authors:  S Krugman; J P Giles; J Hammond
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

3.  Inactivation of hepatitis B virus by intermediate-to-high-level disinfectant chemicals.

Authors:  W W Bond; M S Favero; N J Petersen; J W Ebert
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

4.  Susceptibility of hepatitis B virus to disinfectants or heat.

Authors:  H Kobayashi; M Tsuzuki; K Koshimizu; H Toyama; N Yoshihara; T Shikata; K Abe; K Mizuno; N Otomo; T Oda
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

5.  Death, injury and revival of chemically treated Bacillus subtilis spores.

Authors:  S P Gorman; E P Hutchinson; E M Scott; L M McDermott
Journal:  J Appl Bacteriol       Date:  1983-02

6.  Comparison of the morphological alteration and disintegration test (MADT) and the chimpanzee infectivity test for determination of hepatitis B virucidal activity of chemical disinfectants.

Authors:  O Thraenhart; E K Kuwert; N Scheiermann; R Dermietzel; D Paar; D Maruhn; A Alberti; H J Richter; J Hotz
Journal:  Zentralbl Bakteriol Mikrobiol Hyg B       Date:  1982

7.  The clinical chemistry of chimpanzees: II. Gamma glutamyl transferase levels in hepatitis studies.

Authors:  F P Valenza; E Muchmore
Journal:  J Med Primatol       Date:  1985       Impact factor: 0.667

Review 8.  Primate animal models and titered inocula for the study of human hepatitis A, hepatitis B, and non-A, non-B hepatitis.

Authors:  E Tabor; R H Purcell; R J Gerety
Journal:  J Med Primatol       Date:  1983       Impact factor: 0.667

9.  In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus.

Authors:  J S Tuttleman; J C Pugh; J W Summers
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

10.  The clinical chemistry of chimpanzees. I. Determination of aminotransferase baseline values for hepatitis studies.

Authors:  F P Valenza; E Muchmore
Journal:  J Med Primatol       Date:  1982       Impact factor: 0.667

View more
  8 in total

Review 1.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 2.  Is hepatitis B-virucidal validation of biocides possible with the use of surrogates?

Authors:  Andreas Sauerbrei
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

3.  Quaternary ammonium salt N-(dodecyloxycarboxymethyl)-N,N,N-trimethyl ammonium chloride induced alterations in Saccharomyces cerevisiae physiology.

Authors:  Ewa Oblak; Agata Piecuch; Ewa Maciaszczyk-Dziubinska; Donata Wawrzycka
Journal:  J Biosci       Date:  2016-12       Impact factor: 1.826

Review 4.  Antiseptics and disinfectants: activity, action, and resistance.

Authors:  G McDonnell; A D Russell
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

5.  The physiological and morphological phenotype of a yeast mutant resistant to the quaternary ammonium salt N-(dodecyloxycarboxymethyl)-N,N,N-trimethyl ammonium chloride.

Authors:  Ewa Obłak; Andrzej Gamian; Ryszard Adamski; Stanisław Ułaszewski
Journal:  Cell Mol Biol Lett       Date:  2010-01-29       Impact factor: 5.787

6.  Structurally Related Liposomes Containing N-Oxide Surfactants: Physicochemical Properties and Evaluation of Antimicrobial Activity in Combination with Therapeutically Available Antibiotics.

Authors:  Sara Battista; Pierangelo Bellio; Lorenza Fagnani; Elena Allegritti; Lisaurora Nazzicone; Luciano Galantini; Giuseppe Celenza; Luisa Giansanti
Journal:  Mol Pharm       Date:  2022-02-16       Impact factor: 4.939

7.  Antiseptic Polymer-Surfactant Complexes with Long-Lasting Activity against SARS-CoV-2.

Authors:  Vyacheslav S Molchanov; Andrey V Shibaev; Eduard V Karamov; Viktor F Larichev; Galina V Kornilaeva; Irina T Fedyakina; Ali S Turgiev; Olga E Philippova; Alexei R Khokhlov
Journal:  Polymers (Basel)       Date:  2022-06-16       Impact factor: 4.967

8.  Does limited virucidal activity of biocides include duck hepatitis B virucidal action?

Authors:  Andreas Sauerbrei; Michael Schacke; Brigitte Glück; Uwe Bust; Holger F Rabenau; Peter Wutzler
Journal:  BMC Infect Dis       Date:  2012-10-30       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.